
Upgrades
SVB Leerink upgraded the previous rating for Moderna Inc (NASDAQ:MRNA) from Underperform to Market Perform. Moderna earned $5.24 in the second quarter, compared to $6.46 in the year-ago quarter. The stock has a 52-week-high of $249.42 and a 52-week-low of $115.03. At the end of the last trading period, Moderna closed at $118.38.